188630-47-9
Chemical Structure
SYUIQ-5
- CAS No.: 188630-47-9
- Formula:C20H22N4
- Molecular Weight:318.42
IUPAC Name: (2S,3R,4S,5S,6R)-2-(((2R,3R,4S,5S,6R)-4,5-dihydroxy-2-(((3S,5R,8R,9R,10R,12R,13R,14R,17S)-12-hydroxy-4,4,8,10,14-pentamethyl-17-((S)-6-methyl-2-(((2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-((((2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-((((2S,3R,4S,5R)-3,4,5-trihydroxytetrahydro-2H-pyran-2-yl)oxy)methyl)tetrahydro-2H-pyran-2-yl)oxy)methyl)tetrahydro-2H-pyran-2-yl)oxy)hept-5-en-2-yl)hexadecahydro-1H-cyclopenta[a]phenanthren-3-yl)oxy)-6-(hydroxymethyl)tetrahydro-2H-pyran-3-yl)oxy)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol
InChIKey: CTDCVGDSVHUYMA-UHFFFAOYSA-N
SMILES: CN(C)CCCNC(C1=C(C=CC=C1)N=C23)=C3NC4=C2C=CC=C4
Biological Activity: SYUIQ-5 is a G-quadruplex stabilizer. SYUIQ-5 stabilizes the c-myc promoter G-quadruplex, the VEGF promoter G-quadruplex, and the telomeric G-quadruplex. SYUIQ-5 selectively inhibits telomerase but not Taq polymerase, while decreasing c-myc/hTERT expression and dissociating NM23-H2. SYUIQ-5 induces growth arrest, senescence, autophagy, DNA damage response, telomere shortening, and apoptosis, accompanied by upregulation of p16/p21/p27, decreased TRF2, and pro-catabolic myotube changes. SYUIQ-5 can be used for research on leukemia, colon cancer, cervical cancer, nasopharyngeal carcinoma, Burkitt lymphoma, and sarcopenia[1][2][3][4][5][6][7].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
SYUIQ-5 | 99.03% | SYUIQ-5 is a G-quadruplex stabilizer. SYUIQ-5 stabilizes the c-myc promoter G-quadruplex, the VEGF promoter G-quadruplex, and the telomeric G-quadruplex. SYUIQ-5 selectively inhibits telomerase but not Taq polymerase, while decreasing c-myc/hTERT expression and dissociating NM23-H2. SYUIQ-5 induces growth arrest, senescence, autophagy, DNA damage response, telomere shortening, and apoptosis, accompanied by upregulation of p16/p21/p27, decreased TRF2, and pro-catabolic myotube changes. SYUIQ-5 can be used for research on leukemia, colon cancer, cervical cancer, nasopharyngeal carcinoma, Burkitt lymphoma, and sarcopenia. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Liu JN, et al. Inhibition of myc promoter and telomerase activity and induction of delayed apoptosis by SYUIQ-5, a novel G-quadruplex interactive agent in leukemia cells. Leukemia. 2007 Jun;21(6):1300-2.
- [2]. Zhou JM, et al. Senescence and telomere shortening induced by novel potent G-quadruplex interactive agents, quindoline derivatives, in human cancer cell lines. Oncogene. 2006 Jan 26;25(4):503-11.
- [3]. Zhou WJ, et al. G-quadruplex ligand SYUIQ-5 induces autophagy by telomere damage and TRF2 delocalization in cancer cells. Molecular cancer therapeutics. 2009 Dec;8(12):3203-13. [Content Brief]
- [4]. Wu Y, et al. Stabilization of VEGF G-quadruplex and inhibition of angiogenesis by quindoline derivatives. Biochimica et biophysica acta. 2014 Sep;1840(9):2970-7.
- [5]. Liu HY, et al. New Disubstituted Quindoline Derivatives Inhibiting Burkitt's Lymphoma Cell Proliferation by Impeding c-MYC Transcription. Journal of medicinal chemistry. 2017 Jul 13;60(13):5438-5454.
- [6]. Ou TM, et al. Inhibition of cell proliferation by quindoline derivative (SYUIQ-05) through its preferential interaction with c-myc promoter G-quadruplex. Journal of medicinal chemistry. 2011 Aug 25;54(16):5671-9. [Content Brief]
- [7]. Gerosa L, et al. Murine Myoblasts Exposed to SYUIQ-5 Acquire Senescence Phenotype and Differentiate into Sarcopenic-Like Myotubes, an In Vitro Study. The journals of gerontology. Series A, Biological sciences and medical sciences. 2024 Apr 01;79(4):glae022.
